We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

83 hedge funds and large institutions have $235M invested in OncoMed Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 44 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 14

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

6% more funds holding

Funds holding: 7883 (+5)

7% more call options, than puts

Call options by funds: $1.51M | Put options by funds: $1.41M

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

8% less capital invested

Capital invested by funds: $257M → $235M (-$21.5M)

Holders
83
Holders Change
+5
Holders Change %
+6.41%
% of All Funds
2.24%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
13
Increased
44
Reduced
14
Closed
8
Calls
$1.51M
Puts
$1.41M
Net Calls
+$97K
Net Calls Change
-$103K
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of Montreal
51
Bank of Montreal
Ontario, Canada
$383K -$76.3K -3,095 -15%
New York State Common Retirement Fund
52
New York State Common Retirement Fund
New York
$357K +$391K +15,861 New
RhumbLine Advisers
53
RhumbLine Advisers
Massachusetts
$322K +$60.8K +2,465 +21%
Citigroup
54
Citigroup
New York
$309K -$12.8K -521 -4%
AllianceBernstein
55
AllianceBernstein
Tennessee
$288K +$96.2K +3,900 +44%
AIG
56
American International Group
New York
$252K +$35.6K +1,445 +15%
NFA
57
Nationwide Fund Advisors
Ohio
$246K +$40.4K +1,640 +18%
MLICM
58
Metropolitan Life Insurance Company (MetLife)
New York
$244K +$12.9K +524 +5%
BA
59
BlackRock Advisors
Delaware
$226K +$79.7K +3,232 +47%
D.E. Shaw & Co
60
D.E. Shaw & Co
New York
$215K +$236K +9,555 New
Swiss National Bank
61
Swiss National Bank
Switzerland
$207K +$41.9K +1,700 +23%
BWA
62
Burt Wealth Advisors
Maryland
$169K
GC
63
Globeflex Capital
California
$157K -$592 -24 -0.3%
Federated Hermes
64
Federated Hermes
Pennsylvania
$156K +$171K +6,954 New
Simplex Trading
65
Simplex Trading
Illinois
$137K +$151K +6,131 New
SG Americas Securities
66
SG Americas Securities
New York
$130K +$142K +5,764 New
UBS Group
67
UBS Group
Switzerland
$122K +$24.9K +1,008 +23%
US Bancorp
68
US Bancorp
Minnesota
$64K +$40.4K +1,637 +134%
Legal & General Group
69
Legal & General Group
United Kingdom
$54K
CLOS
70
Compagnie Lombard Odier SCmA
Switzerland
$34K
BNP Paribas Financial Markets
71
BNP Paribas Financial Markets
France
$31.7K +$27.3K +1,106 +367%
TRCT
72
Tower Research Capital (TRC)
New York
$31K +$12.1K +490 +55%
Royal Bank of Canada
73
Royal Bank of Canada
Ontario, Canada
$30K +$28.7K +1,165 +651%
Barclays
74
Barclays
United Kingdom
$9K -$37.1K -1,504 -79%
PMFA
75
Plante Moran Financial Advisors
Michigan
$9K +$9.37K +380 New

OMED Hedge Fund Activity: Q2 2015 in Review

83 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2015, worth a combined $235M — down 8.4% from $257M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new OMED positions and 8 closed out — a net gain of 5 holders — while 44 added to existing stakes and 14 trimmed.

The largest buyer was Cannell & Co, adding an estimated $3.36M. The largest seller was Sectoral Asset Management, cutting an estimated $4.05M.

  • 83 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2015, up from 78 in Q1 2015.
  • Funds reported $235M of OncoMed Pharmaceuticals, Inc. stock for Q2 2015, down 8.4% quarter-over-quarter.
  • 13 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2015 and 8 closed out, a net change of +5 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q2 2015 was Cannell & Co, an estimated $3.36M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2015 was Sectoral Asset Management, an estimated $4.05M sold.

Based on aggregated 13F filings for Q2 2015.